Recent developments in genome-wide association studies (GWAS) have lead to the localization of disease genes for many complex diseases. The scrutiny of the respective publications reveals, first, that statistical analysis is restricted typically to single-marker analysis in the first step, and that, second, the presence of multiple, independently associated SNPs within the same linkage disequilibrium (LD) region is a common phenomenon. Motivated by this observation, we show through a power simulation study that a simultaneous analysis of tightly linked SNPs in the initial GWAS analysis step would lead to increased power, when compared with that in single-marker analysis. This is true for all the three approaches we considered (implementations in BEAGLE, FAMHAP and UNPHASED). The best performance was obtained using a two-marker haplotype analysis. In conclusion, we would expect additional gene findings for re-analyzing successful GWAS with a multi-marker approach. European Journal of Human Genetics (2009Genetics ( ) 17, 1043Genetics ( -1049 doi:10.1038/ejhg.2009 published online 18 February 2009 Keywords: genome-wide association studies; haplotypes; literature study Introduction Biology strongly supports the potential importance of haplotype analysis in genetic association studies.
Introduction
Biology strongly supports the potential importance of haplotype analysis in genetic association studies. 1 Major reasons for haplotype analysis are possible representations of non-genotyped SNPs and the presence of multiple, independent disease markers in the same linkage disequilibrium (LD) region. 2 Nevertheless, evidence that haplotypes actually lead to improved power in genetic association studies has yet to be supplied. Indeed, the increased number of degrees of freedom (d.f.) might over-compensate the benefit achieved from the improved modeling of biology obtainable with haplotypes. Besides that, it is not self-evident whether haplotype assignment is actually a prerequisite for association analysis in LD regions. Clayton et al 3 suggest, as an alternative, the analysis of unphased multi-marker genotype data in these regions. In view of the controversial situation regarding the judgement of haplotype analysis, we conducted a largescale power simulation study for investigating the relative performance of single-marker analysis, simultaneous analysis of unphased genotypes in LD regions -referred to as UMMA (unphased multi-marker analysis) from now onand haplotype analysis in genome-wide association studies (GWAS). The setup of the simulation study was guided by a priori knowledge that has become recently available. Data from the International HapMap Project 4 allowed specifying empirical LD distributions for data simulation. In addition, we extracted information on disease models typical of complex diseases, by studying a comprehensive list of recent publications on GWAS.
Results of literature study
The guidelines for inclusion into the literature study were publication during the time period from January 2005 to June 2008, with publication in a high-impact journal (impact factor 412) and identification of SNP(s) in the first step of GWAS followed by replication. In addition, we restricted ourselves to qualitative phenotypes in order to improve homogeneity with respect to disease model and statistical methods used. Supplementary Table 1 represents citations of 59 publications, 5 -42,44 -64 which met our inclusion criteria. In all publications, association analysis in the initial step was restricted to single-marker analysis. Furthermore, all replicated SNPs had a minor allele frequency 45%, and allelic odds ratios typically ranged from 1.1 to 2.2, with higher exceptions not only for nondisease phenotypes, such as pigmentation for instance, but also for macular degeneration. Thus, the results confirm predictions of the common-disease, common-variant hypothesis. 65 Several publications report follow-up analysis of the LD region around the confirmed SNPs and also test for deviations from a multiplicative SNP model, the presence of multiple independent SNPs within the LD region, haplotype effects or interaction of SNPs from different unlinked regions. Typically, a logistic regression framework was applied. 43 In Supplementary 
Methods
On the basis of information from the literature study, one should expect in reverse that a multi-marker approach in the initial GWA step leads to the identification of even more disease-associated LD regions, such as the identification of those LD regions with multiple variants, which does not reach significance with single-marker tests. Therefore, we tried evaluating the performance of the following GWAS-analysis approaches: single-marker analysis using approach for all pairs of SNPs, including SNP pairs not present in LD. In contrast to this approach, our two-marker strategies have two advantages. First, the number of tests increases only linearly, which guarantees computational feasibility (see Discussion) and, moreover, reduces the price to pay for multiple testing. Second, according to the literature study, there is an increased a priori probability that SNPs pairs from the same LD region are associated with independent contributions to a complex disease, as opposed to that of the general pairs of SNPs. To test our hypothesis that GWA-UMMA-2, GWA-HAP-2 and GWA-HAP-CLUSTER are strategies superior to GWA-1, we conducted a power simulation study, which was conceptually closely related to that earlier presented by de Bakker et al. 69 In brief, we simulated case -control data (5000 individuals) sets based on the CEU trio data from the HapMap ENCODE project. 4 A more detailed description can be found in the appendix. We considered in total, 5000 windows of 62 SNPs. For each window, we obtained 'empirical' population haplotype frequencies using FAMHAP. 70 Next, we designated either one or two SNPs to be 'causal'. Model 1 (M1) was defined by one causal SNP with a multiplicative disease model. The allelic risk was chosen, such that with a complete marker panel a genomewide power of 80% would have been reached at a ¼ 0.05. Model 2 (M2) was defined by the presence of two causal variants without interaction, and model 3 (M3) was a haplotype model with an increased risk ratio for the two-marker haplotype 1 -1 defined by two disease variants. Finally, model 4 (M4) was a recessive haplotype model with two-marker risk haplotype 1 -1. Before data analysis, the marker panels for each marker window were thinned out in such a way that they met varying levels, A -C, of SNP chip coverage, which can be viewed as representing the density of a 300, 500 K and 1 M SNP chip (see appendix, for a more detailed description). To evaluate power, we computed the best P-value minP according to each of the four different analysis approaches, for each simulated and thinned data set. These minP values were multiplied with an empirically determined number of independent tests (see appendix) to obtain genome-wide corrected P-values. Finally, power was computed as the portion of SNP windows with genomewide significance (a ¼ 0.05).
Results
The results of the power study can be found in Table 1 . In model M1 (one disease variant), the power of the GWA-1 approach is 81.1% and, thus, very close to the intended reference power level of 80%. Trivially, power drops, to B72% for both the two-marker approaches in model M1, because of the multiple testing penalty. We discuss the results of the most relevant marker panel C (1 M chip SNP density). Notably, even in the single-disease variant model, M1, power increases (albeit very modestly) from 51.8% for GWA-1 to 52.1 and 52.0% for GWA-UMMA-2 and GWA-HAP-2, respectively. In other words, the increased multiple testing penalty of the two-marker approaches is overcompensated by a power increase caused by the approximation of unobserved disease SNPs with two SNPs through LD. Power of the GWA-CLUSTER approach (50.3%) is somewhat lower, but difference to the other approaches is not significant.
In disease model M2 (two disease variants, but no additional haplotype effect), both GWA-UMMA-2 (79.7%) and GWA-HAP-2 (79.7%) significantly outperform power of the single-marker approach GWA-1 (71.9%). Even though there is no haplotype effect, the GWA-HAP-2 approach performs as good as the GWA-UMMA-approach. It seems that the reduced d.f. of the UMMA-approach and the potential to tag non-genotyped SNPs with the HAPapproach are respective advantages of the two strategies that counterbalance each other. Power of the cluster approach lies in the range of the GWA-1 strategy. We conclude that haplotype clustering yields, at most, small power improvements over single-marker analysis when there is no direct haplotype effect.
In the haplotype model M3, all multi-marker strategies significantly outperform the single-marker strategy. Now, the HAP-CLUSTER approach is most powerful (79.0%), followed by the GWA-HAP-2 (78.3%) and the GWA-UMMA-2 approaches (76.2%). For both the haplotype approaches, comparison with the UMMA approach is significant. In the haplotype model M4, we observe a very similar pattern, the only difference is that now HAP-2 performs best.
Summarizing the results for panel C, one can say that the two-marker-approaches are 'free lunch', in the sense that they do not cost power in the presence of a single disease variant, and that they lead to increased power in the presence of two disease variants within the same marker window, whereas the HAP-CLUSTER approach leads to markedly improved power only when there is a direct haplotype effect on the disease.
The conclusions drawn from the results for panel C also hold for the less-denser panels A and B. It seems that the power gain for the multi-marker approaches is a little bit smaller than for panel C, which indicates that dense marker maps (1 M) are needed for exploiting the benefit of multi-marker approaches.
Finally, we note that we did not observe any qualitative differences in our results, when we evaluated our data according to either the different ENCODE regions or disease allele frequencies.
Discussion
We have shown that, in the presence of multiple, independent disease-associated SNPs within the same LD region, multi-marker approaches lead to improved power when applied in the initial step of the GWAS. According to a simulation setup based on coalescent theory. Thus, our study is also an independent confirmation of earlier results with a different technique. All three multi-marker approaches outperformed the single-marker approach. The power difference between the UMMA-2 (2 d.f.) and the HAP-2 haplotype approach was small, such that both strategies could be advocated. An advantage of the HAP-2 approach is that a fast implementation is part of the FAMHAP software update for GWAS. 72 The haplotype cluster approach performed only slightly better than the two-marker approaches in explicit haplotype disease models (M3 and M4). It is not unlikely that the relative performance of the haplotype cluster approach would have been better in the presence of haplotype models with more than two independent disease markers.
Thus, yet to be gained empirical knowledge on the commonness of such disease models might lead to a different judgement of results. However, in the two-marker model without phase effect (M2), the haplotype cluster method was inferior.
As an alternative to the approaches considered here, multi-marker information can be exploited for imputing SNP genotypes. Marchini et al, 73 for instance, have shown that in the presence of a single, not too common, disease variant, imputing leads to increased power when compared with single-marker analysis. The performance of imputing methods in the presence of multiple disease variants has not been investigated by now. Respective future work could give guidelines on the relative advantages of imputing and multi-marker approaches. Although we believe in multi-marker approaches, we wish to emphasize that quality control is even more important than it is already for single-marker analysis. All used SNPs must pass particularly strong quality criteria, as the impact of a genotyping error increases with haplotype analysis. For instance, a rather small amount of errors, in a sub-batch of the case or control group, can produce quickly non-existing haplotypes, which leads to false positive results.
Our literature study reveals that not a single significant interaction has been found between the genes obtained through the GWAS initiatives of past years. However, we do not think that one should conclude that interaction of unlinked genes does not play an important role in complex diseases. Obviously, there is a strong bias towards noninteracting genes in today's results, as the genes were identified using single-marker strategy. Therefore, we are convinced that genome-wide strategy of testing all SNP pairs suggested by Marchini et al 68 can be useful. Our claim is, however, that before such a strategy, one should first follow a local multi-marker approach, because the a priori probability for true association of a pair of neighboring SNPs is higher than for two random SNPs. Moreover, the two-marker approaches are computationally strongly less intense and, therefore, feasible for the majority of scientific groups.
To obtain genome-wide corrected P-values, the minP values were multiplied with an empirically determined number of independent tests. The respective numbers depend on the SNP panels, and the analysis strategy and can be found in Table A1 . The values were computed as follows: we first assumed that the human genome is separated into distinct marker windows (blocks) and that potential associations due to LD extending outside the marker windows can be ignored for the power calculation. In a recent publication, 76 we have shown how minP adjusted P-values can be computed using an application of the algorithm by Ge et al. 77 This Monte Carlo (MC) simulation-based method leads to corrected P-values, which account for both multiple testing and the dependency of the tests due to LD. In practice, the applicability of this method is restricted to windows of no more than 62 markers in LD. We were interested in genome-wide significance and, hence, small unadjusted P-values. Therefore, it was not computationally feasible to use the MCapproach for the complete simulation study (all marker windows), because small P-values require a large amount of permutations for exact computation. Instead, we evaluated only 10% of the data sets using the MC-approach. We used 10 8 permutation replicates for each data set. For each of these data sets, we obtained the empirical number of independent tests per window by dividing the adjusted minP value by minP, a number typically smaller than the number of tests conducted within each window. Next, we took the average (for each panel and analysis strategy) of empirical adjustment factors computed in this way and applied this average to the minP values of the remaining 90% of simulated data sets. Then, we multiplied the adjusted minP values by the number of marker windows in the genome. Computing 4 000 000/62 ¼ 64 516 yields the number of marker windows, if we assume 4 000 000 million SNPs to be present in the whole genome. Note that the empirical number of independent tests for a complete marker panel of 1 320 000 found by us comes rather close to the number of 1 000 000 independent regions in the genome postulated recently. 78 Finally, genome-wide power was calculated as the portion of windows with corrected minP reaching genome-wide significance. Adjustment factors for the cluster approach were computed analogously. For this approach, we used the permutational P-values provided by BEAGLE 78 for a portion of the windows and scaled up to all windows in the same way as before.
Supplementary Information accompanies the paper on European Journal of Human Genetics website (http://www.nature.com/ejhg) Joint analysis of tightly linked SNPs in GWAS T Becker and C Herold
